Abstract
Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3% and those with low expression 65. 4% (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2% and those with low expression was 75. 5% (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0% and those with low expression was 68. 2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0% and those with low expression was 63. 4% (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 911-915 |
| Number of pages | 5 |
| Journal | Chinese Journal of Oncology |
| Volume | 33 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 23 2011 |
Fingerprint
Keywords
- Cdc7
- Lymphoma, non-hodgkin
- MCM2
- Prognosis
ASJC Scopus subject areas
- Medicine(all)
Cite this
Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma. / Hou, Yun; Wang, Hua Qing; Fu, Kai; Zhang, Hui Lai; Qian, Zheng Zi; Qiu, Li Hua; Li, Wei; Zhou, Shi Yong; Li, Lan Fang; Hao, Xi Shan.
In: Chinese Journal of Oncology, Vol. 33, No. 12, 23.12.2011, p. 911-915.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma
AU - Hou, Yun
AU - Wang, Hua Qing
AU - Fu, Kai
AU - Zhang, Hui Lai
AU - Qian, Zheng Zi
AU - Qiu, Li Hua
AU - Li, Wei
AU - Zhou, Shi Yong
AU - Li, Lan Fang
AU - Hao, Xi Shan
PY - 2011/12/23
Y1 - 2011/12/23
N2 - Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3% and those with low expression 65. 4% (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2% and those with low expression was 75. 5% (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0% and those with low expression was 68. 2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0% and those with low expression was 63. 4% (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.
AB - Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3% and those with low expression 65. 4% (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2% and those with low expression was 75. 5% (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0% and those with low expression was 68. 2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0% and those with low expression was 63. 4% (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.
KW - Cdc7
KW - Lymphoma, non-hodgkin
KW - MCM2
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84862936263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862936263&partnerID=8YFLogxK
U2 - 10.3760/cma.j.issn.0253-3766.2011.12.007
DO - 10.3760/cma.j.issn.0253-3766.2011.12.007
M3 - Article
C2 - 22340100
AN - SCOPUS:84862936263
VL - 33
SP - 911
EP - 915
JO - Chinese Journal of Oncology
JF - Chinese Journal of Oncology
SN - 0253-3766
IS - 12
ER -